Vera Therapeutics Statistics
Total Valuation
VERA has a market cap or net worth of $3.21 billion. The enterprise value is $2.58 billion.
Important Dates
The next estimated earnings date is Tuesday, May 5, 2026, before market open.
| Earnings Date | May 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
VERA has 71.36 million shares outstanding. The number of shares has increased by 16.10% in one year.
| Current Share Class | 71.36M |
| Shares Outstanding | 71.36M |
| Shares Change (YoY) | +16.10% |
| Shares Change (QoQ) | +2.79% |
| Owned by Insiders (%) | 0.92% |
| Owned by Institutions (%) | 85.92% |
| Float | 51.44M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 5.31 |
| P/TBV Ratio | 5.32 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 13.64, with a Debt / Equity ratio of 0.13.
| Current Ratio | 13.64 |
| Quick Ratio | 13.43 |
| Debt / Equity | 0.13 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -41.89 |
Financial Efficiency
Return on equity (ROE) is -50.71% and return on invested capital (ROIC) is -30.02%.
| Return on Equity (ROE) | -50.71% |
| Return on Assets (ROA) | -28.36% |
| Return on Invested Capital (ROIC) | -30.02% |
| Return on Capital Employed (ROCE) | -46.31% |
| Weighted Average Cost of Capital (WACC) | 10.60% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.20M |
| Employee Count | 249 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, VERA has paid $1,000 in taxes.
| Income Tax | 1,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +104.54% in the last 52 weeks. The beta is 1.17, so VERA's price volatility has been higher than the market average.
| Beta (5Y) | 1.17 |
| 52-Week Price Change | +104.54% |
| 50-Day Moving Average | 41.33 |
| 200-Day Moving Average | 33.81 |
| Relative Strength Index (RSI) | 65.89 |
| Average Volume (20 Days) | 1,363,182 |
Short Selling Information
The latest short interest is 8.25 million, so 11.56% of the outstanding shares have been sold short.
| Short Interest | 8.25M |
| Short Previous Month | 7.64M |
| Short % of Shares Out | 11.56% |
| Short % of Float | 16.04% |
| Short Ratio (days to cover) | 7.00 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -315.47M |
| Pretax Income | -299.61M |
| Net Income | -299.62M |
| EBITDA | -315.01M |
| EBIT | -315.47M |
| Earnings Per Share (EPS) | -$4.66 |
Full Income StatementBalance Sheet
The company has $714.59 million in cash and $77.31 million in debt, with a net cash position of $637.28 million or $8.93 per share.
| Cash & Cash Equivalents | 714.59M |
| Total Debt | 77.31M |
| Net Cash | 637.28M |
| Net Cash Per Share | $8.93 |
| Equity (Book Value) | 604.52M |
| Book Value Per Share | 8.48 |
| Working Capital | 675.43M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$241.10 million and capital expenditures -$630,000, giving a free cash flow of -$241.73 million.
| Operating Cash Flow | -241.10M |
| Capital Expenditures | -630,000 |
| Depreciation & Amortization | 468,000 |
| Net Borrowing | 23.34M |
| Free Cash Flow | -241.73M |
| FCF Per Share | -$3.39 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
VERA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -16.10% |
| Shareholder Yield | -16.10% |
| Earnings Yield | -9.32% |
| FCF Yield | -7.52% |
Analyst Forecast
The average price target for VERA is $81.30, which is 80.51% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $81.30 |
| Price Target Difference | 80.51% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
